Ruxolitinib for treating polycythaemia vera

Cancer

Blood and Immune System

12 July 2022

Published on 12 Jul 2022
Last Updated on 12 Jul 2022

Guidance Recommendations

The Ministry of Health's Drug Advisory Committee has not recommended ruxolitinib 5 mg tablet for listing on the Medication Assistance Fund (MAF) for treating patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea, in view of low clinical need, and uncertain clinical and cost-effectiveness compared with subsidised alternatives.

Clinical indication, subsidy class and MediShield Life claim limit for ruxolitinib are provided in the Annex.

Ruxolitinib for treating polycythaemia vera (12 Jul 22) [PDF, 12 KB]

Ruxolitinib for treating polycythaemia vera PES (12 Jul 22) [PDF, 118 KB]